LG-2527
From Wikipedia, the free encyclopedia
This is an old revision of this page, as edited by Vanished user 0x8cSXE0x6 (talk | contribs) at 13:32, 25 June 2018. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 13:32, 25 June 2018 by Vanished user 0x8cSXE0x6 (talk | contribs)
| Clinical data | |
|---|---|
| Drug class | Progestin; Progestogen |
LG-2527 is a nonsteroidal progestin which was under development by Ligand Pharmaceuticals and Wyeth for the treatment of menopausal symptoms and breast cancer but was never marketed.[1] It reached the preclinical stage of development prior to the discontinuation of its development in early 2001.[1]
References
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
Retrieved from "https://en.wikipedia.org/w/index.php?title=LG-2527&oldid=847453756"
Hidden categories:
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- All stub articles